Respiratory Syncytial Virus Infection Clinical Trial
Official title:
A One-Year Observational Study of Palivizumab in Infants at Risk for Respiratory Syncytial Virus Infection in Latin America
The study was designed to gather information regarding the use of palivizumab for the prophylaxis for respiratory syncytial virus (RSV) infection in high-risk infants in selected countries within Latin America.
RSV causes significant disease. There is a paucity of data from developing countries even
though existing data clearly indicate that RSV accounts for a high proportion of acute
respiratory illnesses (ARIs) in children.
This is a multi-center study in a cohort of infants at risk for RSV infection in Latin
America who have received palivizumab in the usual manner in accordance with the terms of
marketing authorization with regard to dose, population and indication. Enrolled
participants were followed for one year after their first dose of palivizumab.
Epidemiological and clinical data as well as information about compliance, hospitalizations
and safety was collected.
;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02016690 -
Synagis® Liquid 50mg, 100mg for Intramuscular Injection Special Investigation in Immuno Compromised Children With Synagis
|
N/A | |
| Completed |
NCT01107535 -
Effectiveness of Synagis (Palivizumab) Immunoprophylaxis in Preterm Infants With High Risk of Severe Respiratory Syncytial Virus (RSV) Infection
|
N/A | |
| Completed |
NCT04491877 -
Study of an Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers
|
Phase 1/Phase 2 | |
| Completed |
NCT05987072 -
A Study to Learn How the Study Medicine Called Sisunatovir is Tolerated and Acts in the Bodies of Chinese Healthy Adults.
|
Phase 1 | |
| Completed |
NCT01006629 -
Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children
|
Phase 2/Phase 3 | |
| Completed |
NCT00593918 -
Innate Immunity and Respiratory Syncytial Virus (RSV) Infection in Children
|
N/A | |
| Recruiting |
NCT06134648 -
Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate
|
Phase 1/Phase 2 | |
| Completed |
NCT03473002 -
A Safety and Immunogenicity Study of Intranasal Sendai Virus Vectored Respiratory Syncytial Virus (SeVRSV) Vaccine in Healthy Adults
|
Phase 1 | |
| Completed |
NCT02135614 -
Efficacy, Pharmacokinetics, and Safety of Presatovir in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection
|
Phase 2 | |
| Completed |
NCT01909843 -
ALX-0171 Safety Study in Adults With Hyperresponsive Airways
|
Phase 1 | |
| Recruiting |
NCT06206720 -
A Study of Deuremidevir Hydrobromide for Suspension in Chinese Infants Hospitalized With RSV
|
Phase 2 | |
| Completed |
NCT02254421 -
Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract
|
Phase 2 | |
| Recruiting |
NCT06237296 -
Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and Older
|
Phase 1 | |
| Completed |
NCT01537198 -
Surveillance of Synagis in Korean Pediatric Patients
|
N/A | |
| Active, not recruiting |
NCT05687279 -
Study on a Live-attenuated Respiratory Syncytial Virus Vaccine for Assessment of Safety, Transmissibility, and Genetic Stability of the Vaccine Virus Among Close Contacts in Infants and Toddlers 6 to < 24 Months of Age in Puerto Rico (USA)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06079320 -
A Study to Learn About the Study Medicine Sisunatovir in Adults With Respiratory Syncytial Virus (RSV) Infection
|
Phase 2/Phase 3 | |
| Completed |
NCT06424795 -
Molecular and Microbiome/Metagenome Correlates of Recurrent Wheeze in RSV Infected Infants
|
||
| Completed |
NCT02309320 -
A Multicentre Study in Otherwise Healthy Infants and Toddlers Hospitalised For and Diagnosed With RSV Lower Respiratory Tract Infection to Evaluate the Safety, Tolerability, and Clinical Activity of ALX-0171
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06194318 -
First-in-human Safety and Immunogenicity Study of SCB-1019 in Healthy Adults
|
Phase 1 | |
| Completed |
NCT01466062 -
Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions
|
Phase 3 |